BodyTel, GlucoTel Technical Files for CE Certification

January 8, 2008 - BodyTel Scientific Inc., (OTCBB:BDYT) the developer of wireless telemedical measuring devices, announced that its wholly owned subsidiary BodyTel Europe GmbH, legal manufacturer of the blood glucose monitoring and diabetes management system GlucoTel, has submitted the GlucoTel Technical File for regulatory review to the designated European Notified Body... BodyTel's Press Release-

Insulet and DexCom , Development Agreement

January 7, 2008 - Insulet Corporation (NASDAQ: PODD), the leader in wearable insulin pump technology with its OmniPod Insulin Management System, and DexCom, Inc. (NASDAQ: DXCM), a leading provider of continuous glucose monitoring systems for people with diabetes, announced they have signed a development agreement to integrate DexCom's continuous glucose monitoring technology into the wireless, handheld OmniPod System Personal Diabetes Manager (PDM). In addition to programming the patient's insulin delivery, the PDM with integrated DexCom technology will receive and display continuous glucose readings from DexCom's wearable sensor transmitter... DexCom's Press Release - Insulet's Press Release -

VIVUS , Extension Study with Qnexa for Diabetes

Jan 09, 2008 - VIVUS, Inc (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced it has initiated a six-month extension study for patients currently enrolled in the OB-202 diabetes study. The OB-202 study is a 28 week, randomized, double blind, placebo controlled, efficacy and safety study of Qnexa(TM) in the glycemic management of obese Type 2 diabetics. The newly initiated study, DM-230, will allow subjects to continue, in a blinded fashion as randomized, in the study for an additional 28 weeks... VIVUS ' Press Release -

DiObex, Patent for the Prevention of Insulin-Induced Hypoglycemia

January 8, 2008 - DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced that it has secured a critical patent from the U.S. Patent and Trademark Office for the use of very low dose glucagon, or DIO-901 , in the prevention of insulin-induced hypoglycemia in diabetes patients. The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon... DiObex' Press Release-

DIAMYD, PHASE III TRIAL WITH DIABETES VACCINE

December 21, 2007 – Diamyd Medical announced today that it has filed an Investigational New Drug (IND) application for a pivotal US Phase III clinical trial with the Diamyd® therapeutic vaccine in recent onset type 1 diabetes patients. The application was submitted to the US Food and Drug Administration (FDA)... The Diamyd® therapeutic vaccine is intended to arrest or slow down the autoimmune destruction of insulin producing beta cells in type 1 diabetes... Diamyd's Press Release -

Adolor , Phase 2a Study of Delta Agonist ADL5859 in Neuropathic Pain

Dec. 14, 2007--Adolor Corporation (Nasdaq: ADLR) announced the initiation of a third Phase 2a study of ADL5859, a novel Delta opioid agonist in development for the treatment of pain. Study 33CL231 will explore the analgesic efficacy of ADL5859 in treating pain associated with diabetic peripheral neuropathy . Recently, Adolor and Pfizer Inc (NYSE: PFE) entered into a collaboration... Adolor's Press Release -

Access Pharmaceuticals, Reduce Glucose Levels in Pre-clinical Testing of Cobalamin Oral Insulin

Dec. 7 , 2007 - Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned... [PDF] Access Pharmaceuticals' Press Release -

Keryx , Sulodexide Phase 3 study to continue without modification

Dec. 5, 2007 - Keryx Biopharmaceuticals (Nasdaq: KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy , recently met to evaluate the data from the ongoing Phase 3 trial... Keryx Biopharmaceuticals' Press Release -

Targacept , TC-6499, Neuropathic Pain Candidate

December 10, 2007 - Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone payment to Targacept under the terms of its alliance agreement with GlaxoSmithKline...Neuropathic pain is characterized as severe, stabbing, burning or tingling and is most often associated with diabetes mellitus... Targacept's Press Release -

Trinity Biotech, FDA Clearance of TRIstat Point-of-Care HbA1c Test

November 29th, 2007 - Trinity Biotech plc (NASDAQ: TRIB) a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that the US Food and Drug Administration has given clearance to market the rapid, point-of-care TRIstat™ HbA1c system... [PDF] Trinity Biotech's Press Release -

Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy

Dec 03, 2007 - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies... EpiCept 's Press Release -